"These results are important for patients who are struggling to control their glucose levels without resorting to daily insulin injections," said Professor Stephan Jacob, M.D, medical director of the Albert Schweitzer Klinik, Knigsfeld, Germany. "The findings suggest that weight loss with Xenical plus diet may provide physicians with another tool to control blood sugar in overweight or obese patients with type 2 diabetes, and prolong the utility of oral anti-diabetes medications."
This data should come as welcome news to physicians in their ongoing battle to control glucose levels in this difficult to treat patient group.
Researchers analysed data from seven double-blind, placebo-controlled trials of Xenical in overweight or obese patients with type 2 diabetes who were being treated with oral anti-diabetic medications. Patients were randomised to receive either Xenical 120 mg or placebo three times per day.
A sub-group of patients receiving maximal or near maximal doses of either metformin (2000 mg) or sulfonylureas (80% of standardised dose) was identified. This group was analysed to determine treatment effects on HbA1c levels and fasting plasma glucose (FPG) both measures of glycaemic control. In the metformin group, researchers found that, compared to the placebo group, Xenical had a significantly greater impact on both HbA1c (-0.81% Xenical vs. -0.38% placebo) and FPG levels (-1.74 mmol/L Xenical vs. -0.38 mmol/L placebo). In pat
Contact: Liz Gofton
Shire Health International